Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Diaceutics PLC specializes in providing data analytics and consulting services to the pharmaceutical industry, focusing on personalized medicine and diagnostic testing. Its unique position stems from its proprietary platform, which integrates real-world data to optimize patient access to targeted therapies, primarily in the oncology sector across North America and Europe.
Diaceutics generates revenue by offering analytics and consulting services that help pharmaceutical companies identify and implement personalized treatment pathways. Its competitive advantage lies in its extensive database of patient and diagnostic data, allowing for tailored solutions that enhance patient outcomes and optimize drug launch strategies.
Adoption rates of personalized medicine in oncology
Partnerships with pharmaceutical companies for data analytics
Regulatory changes affecting diagnostic testing
Growth in the global oncology market
Technological disruption in diagnostic methodologies
Regulatory changes impacting the pharmaceutical industry
Emergence of new analytics platforms from competitors
Increased competition from in-house analytics teams at pharmaceutical companies
Low net income margins may limit reinvestment capacity
Dependence on a few key clients for a significant portion of revenue
moderate - The demand for diagnostic services is somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP growth.
Interest rates have a minimal direct impact on Diaceutics, but higher rates could affect pharmaceutical clients' capital expenditures and R&D budgets, indirectly influencing demand for analytics services.
minimal - The company has low debt levels (Debt/Equity of 0.03), reducing sensitivity to credit conditions.
growth - Investors are likely attracted to the potential for high revenue growth in the personalized medicine sector.
moderate - The stock has shown a 1-year return of 25.3%, indicating some volatility but also growth potential.
